Now showing items 1-10 of 10

    • Advances in the Treatment of Monoclonal Gammopaties: The Emerging Role of Targeted Therapy in Plasma Cell Dyscrasias 

      Roccaro, Aldo M.; Ghobrial, Irene; Blotta, Simona; Treon, Steven P.; Malagola, Michele; Anderson, Kenneth Carl; Russo, Domenico (Dove Medical Press, 2008)
      The paradigm for the treatment of monoclonal gammopaties has dramatically changed: therapeutic options in multiple myeloma (MM) have evolved from the introduction of melphalan and prednisone in the 1960s, high-dose ...
    • Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma 

      Bianchi, Giada; Ghobrial, Irene M. (2014)
      Clonal heterogeneity and clonal evolution have emerged as critical concepts in the field of oncology over the past four decades, largely thanks to the implementation of novel technologies such as comparative genomic ...
    • Bone Marrow Microenvironment in Multiple Myeloma Progression 

      Manier, S.; Sacco, A.; Leleu, X.; Ghobrial, Irene; Roccaro, Aldo M. (Hindawi Publishing Corporation, 2012)
      Substantial advances have been made in understanding the biology of multiple myeloma (MM) through the study of the bone marrow (BM) microenvironment. Indeed, the BM niche appears to play an important role in differentiation, ...
    • Candidate genes of Waldenström’s macroglobulinemia: current evidence and research 

      Bianchi, Giada; Sacco, Antonio; Kumar, Shaji; Rossi, Giuseppe; Ghobrial, Irene; Roccaro, Aldo (Dove Medical Press, 2013)
      Waldenström’s macroglobulinemia (WM) is a relatively uncommon, indolent malignancy of immunoglobulin M-producing B cells. The World Health Organization classifies it as a lymphoplasmacytic lymphoma and patients typically ...
    • Front Line Treatment of Elderly Multiple Myeloma in the Era of Novel Agents 

      Venon, Marie-Dominique; Roccaro, Aldo M.; Gay, Julie; Moreau, Anne-Sophie; Dulery, Remy; Facon, Thierry; Ghobrial, Irene; Leleu, Xavier (Dove Medical Press, 2009)
      Melphalan combined with prednisone (MP) has long been the historical treatment of reference for a large proportion of elderly myeloma (MM) patients ineligible for autologous stem cell transplantation, and is still the ...
    • Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma 

      Zhang, Wenjing; Wang, Yaoyu E.; Zhang, Yu; Leleu, Xavier; Reagan, Michaela; Zhang, Yong; Mishima, Yuji; Glavey, Siobhan; Manier, Salomon; Sacco, Antonio; Jiang, Bo; Roccaro, Aldo M.; Ghobrial, Irene M. (Public Library of Science, 2014)
      Epigenetic changes frequently occur during tumorigenesis and DNA hypermethylation may account for the inactivation of tumor suppressor genes in cancer cells. Studies in Multiple Myeloma (MM) have shown variable DNA methylation ...
    • The Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigms 

      Richardson, Paul Gerard Guy; Laubach, Jacob; Schlossman, Robert Lawrence; Ghobrial, Irene; Mitsiades, Constantine S; Rosenblatt, Jacalyn Mara; Mahindra, Anuj; Raje, Noopur; Munshi, Nikhil C; Anderson, Kenneth Carl (Blackwell Publishing Ltd, 2011)
      Osteolytic bone disease is a hallmark of symptomatic multiple myeloma. Bisphosphonates have been the mainstay of treatment to preserve skeletal integrity and prevent skeletal-related events in patients with myeloma-related ...
    • miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer 

      Corcoran, Claire; Rani, Sweta; Breslin, Susan; Gogarty, Martina; Ghobrial, Irene M; Crown, John; O’Driscoll, Lorraine (BioMed Central, 2014)
      Background: While the treatment of HER2 over-expressing breast cancer with recent HER-targeted drugs has been highly effective for some patients, primary (also known as innate) or acquired resistance limits the success of ...
    • Role of Dual PI3/Akt and mTOR Inhibition in Waldenstrom's Macroglobulinemia 

      Sacco, Antonio; Roccaro, Aldo M.; Ghobrial, Irene M. (Impact Journals LLC, 2010)
      Tumorigenesis occurs due to synergistic interactions from a complex of signal transduction processes, including multiple onco-proteins and tumor suppressors such as Ras, Myc, PI3K/Akt/mTOR, Her-2/Neu, p53 and PTEN. ...
    • Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ 

      Reagan, Michaela Ruth; Seib, F. Philipp; McMillin, Douglas William; Sage, Elizabeth K.; Mitsiades, Constantine S.; Janes, Sam M.; Ghobrial, Irene; Kaplan, David L. (Korean Breast Cancer Society, 2012)
      Purpose Tumor-specific delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), an apoptosis-inducing peptide, at effective doses remains challenging. Herein we demonstrate the utility of a scaffold-based ...